Apellis Pharmaceuticals (APLS) Still Has No FDA AdCom, Which is a Positive - Cowen
Tweet Send to a Friend
Cowen analyst Phil Nadeau reiterated an Outperform rating and $70.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS) after the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
